Jayson Bedford

“Maybe just for Jamie, on the EUP, how long will it take you to fully implement the program, meaning when do you expect to see the 3% to 5% gross impact on revenue per procedure?”

“I want to go back to the international medtech business. Is there any way to quantify the impact of the dynamics in the Mideast and VBP? And then Tim, I wanted to ask about international surgery.”

“I guess my first question is, are you starting to see nerve tape used over AxaGuard, and how do you position the two in the portfolio?”

“I wanted to ask on the system strength, which at 12% obviously stood out. Is any of the strength here reflective of an uptick in the replacement cycle, or is that still on the come?”

“Just a clarification and then a question. I missed the comments around NCS ads. Was the takeaway that 2Q ads were similar to 1Q? And then my question is really, it's tough not to notice the OPEX leverage.”